Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRX Pharmaceuticals Inc (NRXP) provides investors and healthcare professionals with critical updates on novel therapies for central nervous system disorders and pulmonary diseases. This page aggregates official press releases, clinical trial developments, and regulatory milestones related to the company’s NMDA platform and ketamine-based treatments.
Visitors gain access to verified information about NRX-100 and NRX-101 – investigational therapies targeting suicidal depression and bipolar disorder – along with strategic initiatives through subsidiary HOPE Therapeutics. The resource prioritizes clarity in explaining complex biopharmaceutical concepts while maintaining scientific precision.
Key content includes updates on Fast Track designations, New Drug Application progress, and innovations in preservative-free drug formulations. The curated news collection serves as a decision-making tool for tracking the company’s progress in addressing unmet medical needs through rigorous clinical research.
Bookmark this page for streamlined access to NRX Pharmaceuticals’ latest developments in interventional psychiatry and small-molecule therapeutics. Check regularly for authoritative updates on pipeline advancements and regulatory strategy execution.
NRx Pharmaceuticals has transitioned to U.S.-based manufacturing for its investigational drug NRX-101, targeting suicidal bipolar depression. The FDA has received updated manufacturing files, facilitating an upcoming Phase 3 trial aimed at patients with acute suicidal ideation. The drug, a combination of D-cycloserine and lurasidone, has been shown to significantly reduce both depression and suicidality in previous trials. This new capability could expedite the drug's market launch while addressing a critical unmet need in mental health care.
NRx Pharmaceuticals (Nasdaq: NRXP) has secured approximately $11 million in unsecured debt financing from Streeterville Capital, aimed to boost the development of its lead drug NRX-101 for treating suicidal bipolar depression and PTSD. With about $10 million earmarked for these programs, the funds will also support corporate operations. The financing comes with a 9% interest rate and a maturity of 18 months. The company is optimistic about the potential of NRX-101, especially after achieving FDA milestones including Breakthrough Therapy Designation.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that CEO Stephen Willard and executives will provide a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 9:00 AM ET. This presentation will cover the company’s progress, particularly focusing on NRX-101, a novel treatment for severe bipolar depression. NRX-101 has received FDA Breakthrough Therapy designation and is expected to begin its registration trial in Q4 2022. The event is accessible via webcast with a replay available for 30 days.
NRx Pharmaceuticals (Nasdaq: NRXP) hosted its Q2 2022 earnings call on August 15, 2022, announcing financial results and clinical updates. The company is focused on its lead compound NRX-101, which has received Breakthrough Therapy designation from the FDA for severe bipolar depression with acute suicidal ideation. A Phase 2 trial for NRX-101 has commenced, aiming for data readout by early 2023. Q2 2022 net loss was $7.0 million, an increase from $0.1 million in Q2 2021, while cash reserves decreased to $24.5 million. The company plans to maintain operations through August 2023.
NRx Pharmaceuticals, based in Radnor, PA, will announce its second quarter 2022 financial results on August 15, 2022, before market open. A conference call will follow at 8:30 AM ET, offering a corporate and clinical update along with a Q&A session. Investors can submit questions via email by 4:00 PM ET on August 12. The call can be accessed by dialing (844) 826-3033 (U.S.) or (412) 317-5185 (International) and the replay will be available on the company's website afterwards.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) appointed Stephen Willard as CEO and Board member, succeeding interim CEO Robert Besthof, who returns to his previous roles. Willard, a veteran in biotechnology management, previously led Cellphire Therapeutics and Flamel Technologies. His expertise includes law and finance, and he’s a National Science Board appointee (2018-2024). Under Willard’s leadership, NRx aims to advance NRX-101, a promising treatment for bipolar depression and acute suicidal ideation, with plans for FDA registration trials.
NRx Pharmaceuticals announced that the FDA has declined to issue an Emergency Use Authorization for ZYESAMI® (aviptadil) for a subgroup of critically ill COVID-19 patients who were also treated with Remdesivir. This decision follows the previously communicated futility of the ACTIV-3b / TESICO Study. The company will now focus on the development of NRX-101, a treatment for bipolar depression with suicidality. Despite the setback with ZYESAMI®, NRX-101 has received Breakthrough Therapy designation from the FDA, indicating ongoing potential for future development.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that the FDA denied its request for Breakthrough Therapy designation for ZYESAMI (aviptadil). The decision comes despite positive findings from a post-hoc analysis in patients with Critical COVID-19. The company is now focusing on advancing NRX-101, a BTD compound for Bipolar Depression with suicidal ideation, with topline data expected by year-end. NRx plans to explore ZYESAMI for other indications. The interim CEO expressed disappointment but reaffirmed the commitment to address high unmet patient needs.
NRx Pharmaceuticals (Nasdaq: NRXP) announced the appointment of Seth Van Voorhees, Ph.D., as Chief Financial Officer and Treasurer, effective June 13, 2022. His extensive experience in corporate finance and investment banking aims to enhance the company's focus on its psychiatry franchise, particularly the development of NRX-101, a therapy for severe bipolar depression. The company is advancing clinical trials, including a Phase II trial for bipolar patients with acute suicidal ideation. Interim CEO Robert Besthof thanked former CFO Ira Strassberg for his contributions to internal controls and finance functions.